Early treatment with Roche's OCREVUS leads to reduced disease progression and healthcare costs; nine-year safety data reinforce favourable benefit-risk profile October 26, 2022October 26, 2022 by / Share This.....LinkedinTwitterFacebookGoogleEmailRelated News: New data from phase III HAVEN 6 study reinforce…Data up to 8-years for Roche’s OCREVUS (ocrelizumab)…Interim data from phase III HAVEN 6 study…New data reinforce the benefit of early preventative…New data for Roche’s Hemlibra reinforce safety…New data for Roche’s OCREVUS (ocrelizumab) show…Share this:Click to share on Twitter (Opens in new window)Click to share on Facebook (Opens in new window)
